43.70 -0.09 (-0.21%)
After hours: 4:46PM EDT
|Bid||43.61 x 800|
|Ask||43.92 x 46000|
|Day's Range||43.76 - 44.29|
|52 Week Range||33.20 - 44.29|
|PE Ratio (TTM)||11.70|
|Forward Dividend & Yield||1.36 (3.11%)|
|1y Target Est||N/A|
NEW YORK, Sept. 25, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Results from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs 14.7 months for men who received placebo plus ADT(1) ...
NEW YORK, NY / ACCESSWIRE / September 24, 2018 / It was a good day for biotech stocks Pfizer and Oragenics this past Friday. While Oragenics did not have any news, the company is expected to present data ...
Pfizer Inc. (PFE) announced today that its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077, received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older.2 Pfizer expects to start Phase 3 trials in a few months.
NEW YORK, NY / ACCESSWIRE / September 19, 2018 / U.S. markets closed up Tuesday on the strength of upbeat corporate earnings and strong economic data. On Tuesday, China announced tariffs of between 5 to ...
—Findings from sensitivity and post-hoc analyses were presented during a Late Breaking Clinical Trials Session at the Heart Failure Society of America 22nd Annual Scientific Meetin
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 30, 2018. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors.
Pfizer Inc. (PFE) today announced results from its Phase 2a study of PF-06651600, an oral Janus kinase (JAK) 3 inhibitor, and PF-06700841, a tyrosine kinase (TYK) 2/JAK1 inhibitor, compared to placebo, in patients with moderate to severe alopecia areata (AA), an autoimmune disease characterized by hair loss and often associated with profound psychological consequences. Both JAK inhibitors met the primary efficacy endpoint in improving hair regrowth on the scalp relative to baseline at week 24 (33.6 points and 49.5 points for JAK3 and TYK2/JAK1, respectively) as measured by the Severity of Alopecia Tool (SALT) score (100 point scale).
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Executive Vice President, Business Operations, and Chief Financial Officer, at the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018 at 2:55 p.m. Eastern Daylight Time. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com/investors beginning today. Visitors will be able to listen to an archived copy of the webcast at www.pfizer.com/investors.
The Breakthrough Therapy designation for alopecia areata was supported by positive results from a Phase 2 study, which will be presented during the late-breaking news session at the 27th European Academy of Dermatology and Venerology (EADV) Congress in Paris on September 15, 2018.
Pfizer intends to use the net proceeds for general corporate purposes, including to refinance, redeem or repurchase existing debt and to repay a portion of its outstanding commercial paper. Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Morgan Stanley & Co. LLC are acting as joint book-running managers for the offering.
Pfizer Inc. (PFE) announced today that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label extension study (B5161004). The Phase 2 study (B5161002), did not meet its primary efficacy endpoint, which was to demonstrate a difference in the mean change from baseline in 4 Stair Climb (in seconds) following one year of treatment with domagrozumab as compared to placebo in patients with DMD. Pfizer will continue to review the data to better understand any insights they may provide, and will share results with the scientific and patient community.
NEW YORK, NY / ACCESSWIRE / August 28, 2018 / Pfizer announcing positive study results of its drug tafamidis for transthyretin amyloid cardiomyopathy, sent shares of Alynylam Pharmaceuticals skyrocketing on Monday as the company is developing a drug for a similar disease. Pfizer Inc. shares were down almost 2% on Monday despite Wall Street learning that the company may have a potential blockbuster medicine in its hands. A new study has shown that patients who have a rare condition called transthyretin amyloid cardiomyopathy, which can lead to heart failure, lowered their risk of dying by 30 percent after being treated with Pfizer’s tafamidis.
ATTR-ACT Showed that Tafamidis Significantly Reduced the Combination of All-cause Mortality and Cardiovascular-related Hospitalizations
Pfizer Inc. (PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced amendments to the protocols for two registrational Phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI® (enzalutamide) in men with hormone-sensitive prostate cancer (HSPC). ARCHES is a randomized Phase 3 study evaluating the efficacy and safety of enzalutamide plus androgen deprivation therapy (ADT) versus ADT alone in metastatic HSPC patients. Revisions were also made to the protocol for EMBARK, a randomized Phase 3 study of enzalutamide plus leuprolide, enzalutamide monotherapy, and leuprolide alone in men with high-risk non-metastatic HSPC.
MADISON, Wis. and NEW YORK, Aug. 22, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) and Pfizer Inc. (PFE) today announced an agreement through 2021 to co-promote Cologuard, the first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer. Colorectal cancer is recognized as the most preventable yet least prevented form of cancer and remains the second leading cause of cancer death in the U.S., with more than 50,000 deaths each year. Nine out of 10 people survive more than five years when colorectal cancer is diagnosed in Stages I or II, but only one out of 10 people survive more than five years when the disease is diagnosed in Stage IV.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Monday, August 27, 2018 at 9:00 a.m. EDT. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com/investors beginning today. Visitors to www.pfizer.com/investors will be able to view and listen to an archived copy of the webcast of the conference call.
NEW YORK, NY / ACCESSWIRE / August 1, 2018 / Wall Street snapped its losing streak on Tuesday as investors digested better-than-expected quarterly earnings and after the Trump administration appeared to ...
Pfizer Inc. (PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 10 mg twice-daily (BID) for at least eight weeks, followed by XELJANZ 5 mg BID or 10 mg BID, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.1 XELJANZ is the first and only oral therapy and Janus kinase (JAK) inhibitor to be approved for this patient population. In approving XELJANZ for UC, the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has, as part of its assessment, determined XELJANZ to be of significant clinical benefit for patients with UC in comparison with existing therapies.
NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Pfizer Inc. (NYSE: PFE ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 31, 2018 at 10:00 AM Eastern Time. To listen ...
NEW YORK-- -- Second-Quarter 2018 Revenues of $13.5 Billion, Reflecting 2% Operational Growth Second-Quarter 2018 Reported Diluted EPS of $0.65, Adjusted Diluted EPS of $0.81 Raised 2018 Financial Guidance for Adjusted Diluted EPS by $0.05 to a Range of $2.95 to $3.05 Lowered Midpoint of 2018 Revenue Guidance Range by $500 Million Solely to Reflect Recent Unfavorable Changes in Foreign Exchange Rates ...
The European Commission decision marks the approval of Pfizer’s first therapeutic oncology biosimilar
Released today, a new report based on research by the Economist Intelligence Unit (EIU) and sponsored by Pfizer Vaccines assesses why, despite the evidence supporting the medical and cost-saving benefits of preventative healthcare measures, consumers regularly choose not to adopt them. Through interviews with leading international experts, the report reviews the psychological factors affecting consumer and patient decision-making, in relation to their health. The report addresses what policymakers, public health campaigners and healthcare professionals need to do to mitigate these influences, with a particular focus on vaccination.
Stock Research Monitor: LLY, MRK, and NVS LONDON, UK / ACCESSWIRE / July 26, 2018 / If you want a free Stock Review on PFE sign up now at www.wallstequities.com/registration . On Wednesday, benchmark US ...
Pfizer today announced it will increase its commitment to U.S. manufacturing with a $465 million investment to build one of the most technically advanced sterile injectable pharmaceutical production facilities in the world in Portage, Michigan. This U.S. investment will strengthen Pfizer’s capability to produce and supply critical, life-saving injectable medicines for patients around the world. Known as Modular Aseptic Processing (MAP), the new, multi-story, 400,000-square-foot production facility will also support the area economy by creating an estimated 450 new jobs over the next several years.